



Day One Meeting: Objectives and Deliverables

Sandra D. Comer

James P. Zacny



Objectives are a product of two CPDD conferences

- CPDD = College on Problems of Drug Dependence
 - over many years has facilitated the development and refinement of methods for preclinical and clinical ALA of psychoactive drugs
- Conferences:
 - 2003: Abuse Liability Assessment of CNS Drugs
 - 2006: Drug Formulation and Abuse Liability



Each conference had an Expert Panel

- 2003: chaired by Ed Sellers, MD, PhD
- 2006: chaired by Charles Grudzinskas
 - The Expert Panels put forth issues, recommendations, and research priorities
 - One of the recommendations coming out of both conferences and panels was a call for standardization of some outcome measures of human ALA

Abuse Liability Assessment of CNS Drugs

- Following quotes come from the two special issues of Drug and Alcohol Dependence that contained the proceedings of the conferences:
 - **Abuse Liability Assessment of CNS Drugs**
 - Abuse Liability Assessment of CNS Drugs: Conclusions, Recommendations, and Research Priorities. The Expert Panel. *Drug Alcohol Depend* 70S(3):107-114. *chaired by Edward Sellers*
 - **Drug Formulation and Abuse Liability**
 - Impact of Formulation on the Abuse Liability, Safety, and Regulation of Medications: The Expert Panel Report. *Drug Alcohol Depend* 83S(1):77-82. *chaired by Charles Grudzinskas*



2003: Abuse Liability Assessment of CNS Drugs

- Researchers should be encouraged to standardize some psychometric scales (e.g., drug liking)...in order to facilitate comparisons of ALA across research laboratories and drugs.
- Investigators frequently modify assessment instruments or develop new but unvalidated scales...
 - Complicates cross-study comparisons
 - Especially problematic with evaluation of new drugs for which there is uncertainty of the most appropriate methods
 - Leads to use of many *similar but significantly different methods*, which in turn often results in *mixed results that greatly complicate interpretation*



2003: ALA of CNS Drugs (cont.)

- It is anticipated that it may be difficult to reach consensus on a standardized battery and even if developed, investigators may be reluctant to use such a set of assessments.
- At the very least, *a standardized battery could be one component of the evaluation*, leaving investigators free to add other nonstandardized assessments.



2006: Drug Formulation and Abuse Liability

- Continued standardization of the primary outcome measures used in ALA should be encouraged to permit more systematic comparisons across studies.



Abuse Liability Assessment

- Focus for today is on ALA of analgesics
 - **Opioids**
 - Analgesic entities that appear to be mediated by CNS pathway
- Primary entities of interest:
 - Analgesics in development for FDA-approval in which ALA is a requisite



Meeting Objectives

- To present and discuss outcome measures of analgesic abuse liability assessment studies
 - Subjective effects measures
 - Cognitive/psychomotor effects
 - Physiological effects
 - Reinforcing effects
- To reach a consensus on what measures should be recommended for ALA of CNS analgesics



Meeting Deliverable

- Eventually, a manuscript published in a peer-reviewed journal
- Specifically, a consensus document outlining our recommendations for:
 - consideration of certain core outcome measures for the assessment of abuse liability of CNS analgesic drugs
 - with the recognition that these measures can be supplemented by additional measures depending on the specific objectives of the study